Insider Selling: Insmed Incorporated (NASDAQ:INSM) Insider Sells $121,486.47 in Stock

Insmed Incorporated (NASDAQ:INSM) insider Martina M.D. Flammer sold 1,799 shares of the stock in a transaction that occurred on Friday, May 16th. The stock was sold at an average price of $67.53, for a total transaction of $121,486.47. Following the sale, the insider now owns 84,797 shares in the company, valued at $5,726,341.41. This represents a 2.08% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Martina M.D. Flammer also recently made the following trade(s):

• On Thursday, May 15th, Martina M.D. Flammer sold 9,925 shares of Insmed stock. The shares were sold at an average price of $65.47, for a total value of $649,789.75.
• On Wednesday, May 14th, Martina M.D. Flammer sold 1,744 shares of Insmed stock. The shares were sold at an average price of $65.61, for a total transaction of $114,423.84.
• On Tuesday, May 13th, Martina M.D. Flammer sold 8,408 shares of Insmed stock. The shares were sold at an average price of $67.81, for a total value of $570,146.48.

Insmed Stock Down 0.4%

NASDAQ INSM traded down $0.24 on Monday, hitting $67.88. 1,334,593 shares of the company were exchanged, compared to its average volume of 2,325,724. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. The company has a market cap of $12.36 billion, a PE ratio of -12.14 and a beta of 0.84. The stock has a fifty day moving average of $71.57 and a 200-day moving average of $73.16. Insmed Incorporated has a 12 month low of $21.92 and a 12 month high of $84.91.

Insmed (NASDAQ:INSM) last posted its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.36) by ($0.06). The firm had revenue of $92.82 million for the quarter, compared to analyst estimates of $91.63 million. Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. The firm’s quarterly revenue was up 22.9% compared to the same quarter last year. During the same period last year, the company posted ($1.06) earnings per share. As a group, analysts forecast that Insmed Incorporated will post -4.56 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Vanguard Group Inc. lifted its position in Insmed by 0.3% in the 1st quarter. Vanguard Group Inc. now owns 18,268,122 shares of the biopharmaceutical company’s stock valued at $1,393,675,000 after acquiring an additional 49,149 shares in the last quarter. Darwin Global Management Ltd. boosted its holdings in Insmed by 23.5% during the fourth quarter. Darwin Global Management Ltd. now owns 12,960,538 shares of the biopharmaceutical company’s stock worth $894,796,000 after purchasing an additional 2,463,261 shares during the last quarter. Price T Rowe Associates Inc. MD grew its position in Insmed by 1.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 12,923,541 shares of the biopharmaceutical company’s stock worth $985,938,000 after purchasing an additional 219,131 shares in the last quarter. Capital International Investors increased its stake in Insmed by 9.1% in the 4th quarter. Capital International Investors now owns 7,116,997 shares of the biopharmaceutical company’s stock valued at $491,357,000 after buying an additional 593,206 shares during the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of Insmed by 7.2% during the 4th quarter. Geode Capital Management LLC now owns 4,087,143 shares of the biopharmaceutical company’s stock worth $282,243,000 after buying an additional 273,759 shares in the last quarter.

Wall Street Analyst Weigh In

INSM has been the subject of a number of recent research reports. Jefferies Financial Group initiated coverage on Insmed in a report on Tuesday, May 13th. They issued a “buy” rating and a $105.00 target price for the company. Morgan Stanley boosted their target price on shares of Insmed from $85.00 to $90.00 and gave the stock an “overweight” rating in a report on Thursday, February 6th. Cantor Fitzgerald reissued an “overweight” rating on shares of Insmed in a research note on Wednesday, February 19th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $100.00 target price on shares of Insmed in a research report on Wednesday, March 19th. Finally, Wells Fargo & Company upped their price target on Insmed from $85.00 to $107.00 and gave the company an “overweight” rating in a research report on Wednesday, February 19th. One equities research analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $94.63.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.